Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Ordinary Shares, nominal value Euro 0.04 per share
-
Shares outstanding
-
105,371,575
-
Total 13F shares
-
29,331,943
-
Share change
-
-1,072,325
-
Total reported value
-
$161,028,000
-
Put/Call ratio
-
147%
-
Price per share
-
$5.49
-
Number of holders
-
41
-
Value change
-
-$7,201,007
-
Number of buys
-
14
-
Number of sells
-
30
Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) as of Q1 2020
As of 31 Mar 2020,
ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,331,943 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, RTW INVESTMENTS, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., GOLDMAN SACHS GROUP INC, JENNISON ASSOCIATES LLC, Aquilo Capital Management, LLC, Artal Group S.A., DAFNA Capital Management LLC, FMR LLC, and UBS Group AG.
This page lists
41
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.